Finish Line Stock Hits New 52-Week High (FINL)

NEW YORK ( TheStreet) -- Finish Line (Nasdaq: FINL) hit a new 52-week high Friday as it is currently trading at $24.49, above its previous 52-week high of $24.48 with 287,641 shares traded as of 1:20 p.m. ET. Average volume has been 759,900 shares over the past 30 days.

Finish Line has a market cap of $1.06 billion and is part of the services sector and retail industry. Shares are up 25.4% year to date as of the close of trading on Thursday.

The Finish Line, Inc., together with its subsidiaries, operates as a mall-based specialty retailer in the United States. It operates Finish Line stores that offer performance and athletic casual footwear, apparel, and accessories for men, women, and kids. The company has a P/E ratio of 16.9, above the average retail industry P/E ratio of 14.6 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Finish Line as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, revenue growth, reasonable valuation levels, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Finish Line Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Emerging Markets Get Pounded by Trade War Concerns

Emerging Markets Get Pounded by Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns